ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO395

Dysregulation of Thrombo-Inflammatory Biomarkers in ESRD and Their Potentiation with Heart Failure

Session Information

  • Hypertension and CVD: Basic
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Hypertension and CVD

  • 1601 Hypertension and CVD: Basic


  • Robbin, Vanessa, Loyola University Medical Center, Maywood, Illinois, United States
  • Siddiqui, Fakiha, Loyola University Medical Center, Maywood, Illinois, United States
  • Nikolovski, Srdjan, Loyola University Medical Center, Maywood, Illinois, United States
  • Allen, Madeline T., Loyola University Medical Center, Maywood, Illinois, United States
  • Fareed, Jawed, Loyola University Medical Center, Maywood, Illinois, United States
  • Bansal, Vinod K., Loyola University Medical Center Department of Nephrology, Maywood, Illinois, United States

In patients with end-stage renal disease undergoing hemodialysis (ESRD-HD), heart failure with reduced ejection fraction (HFrEF) represents a common comorbidity. Thromboinflammatory processes in both ESRD and HFrEF represent complex pathophysiology, and are demonstrated by dysregulation of thromboinflammatory biomarkers. This study aims to investigate the effects of HFrEF as a comorbidity on these biomarkers in ESRD-HD patients.


Blood samples from 71 ESRD-HD patients and 40 healthy normal controls were analyzed via commercial ELISA and other chromogenic methods for levels of angiopoietin-2, endogenous glycosaminoglycans, FABP, IL-6, LPS, free fatty acids, proBNP, TNFa, VEGF, Vit D, and vWF. Patient groups were stratified into those with or without HFrEF (EF<50%) in the 6 months prior or following the plasma collection using echocardiography records obtained via chart review.


Compared to ESRD-HD alone, a significant increase (p < 0.05) was noted in IL-6 and proBNP, in those with ESRD-HD and HFrEF. Notably, Spearman’s rank correlations were compiled for both groups, and markedly stronger correlations were noted in those with both ESRD-HD and HFrEF. Moreover, PAI-1 and tPA were higher in HFrEF group, suggesting the fibrinolytic deficit.


The dysregulation of thrombo-inflammatory biomarkers in ESRD-HD is amplified in comorbid HFrEF. Correlation among biomarkers in this cohort indicates the mechanisms of thrombo-inflammatory biomarker generation have an integrative process that is shared between the two conditions. The role of fibrinolytic deficit is to be further investigated.